Staying On The FDA’s Right Side: Chinese Device Firms And US Compliance
This article was originally published in PharmAsia News
The nuances of regulatory compliance can be daunting, especially for exporters unfamiliar with the workings of regulations and their enforcers. For Chinese medical device manufacturers, meeting regulatory requirements can be especially difficult to achieve as they face mounting pressure to maintain double-digit growth, launch new products, and beat development cycles, all while operating costs tighten.
You may also be interested in...
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.
Wholesalers are given three more years to set up electronic systems to verify saleable returns under another reprieve from the FDA. Yet the reprieve does not extend to manufacturers, who must respond within 24 hours to wholesalers’ requests to manually verify that a returned product is not suspect.
Agency explains how it will model vaccine authorization process on its licensing process for matters like inspections and lot release.